This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ghoshal, K. Articles by Jacob, S. T. Search for Related Content PubMed PubMed Citation Articles by Ghoshal, K. Articles by Jacob, S. T.

Specific Inhibition of Pre-Ribosomal RNA Processing in Extracts from the Lymphosarcoma Cells Treated with 5-Fluorouracil¹

Department of Pharmacology and Molecular Biology, The Chicago Medical School, North Chicago, Illinois 60064

To elucidate the molecular mechanism by which the potent anticancer drug, 5-fluorouracil (5-FUra), inhibits cell proliferation, the effect of its metabolite, 5-fluorouridine triphosphate, on transcription of rat rRNA gene and processing of pre-rRNA was investigated in S-100 extract from the mouse lymphosarcoma cells. The in vitro processing of pre-rRNA substrate synthesized from the T3 promoter occurred at the correct primary processing site. Replacement of UMP with 5-fluorouridine monophosphate in the rRNA substrate did not affect the pre-rRNA processing. Similar result was obtained when coupled transcription-processing was studied. When the coupled reaction was examined using extracts from the cells treated with 5-FUra, rRNA processing was abolished whereas transcription of rRNA gene was unaffected. Treatment of cells with thymidine along with 5-FUra did not reverse the inhibitory effect of the drug on rRNA processing. In contrast to the effect on rRNA processing, treatment of cells with 5-FUra did not impede the 3' end processing of pre-mRNA. These data show that inhibition of pre-rRNA processing is a major mechanism of action of 5-FUra and suggest that the activity and/or synthesis of a trans-acting factor(s) involved in this reaction is altered by the anticancer drug.

¹ This study is supported by Grant CA 31894 from the National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 11/11/93. Accepted 12/15/93.

This article has been cited by other articles:

				J. Hoskins and J. S. Butler RNA-Based 5-Fluorouracil Toxicity Requires the Pseudouridylation Activity of Cbf5p Genetics, May 1, 2008; 179(1): 323 - 330. [Abstract] [Full Text] [PDF]

				X.-X. Sun, M.-S. Dai, and H. Lu 5-Fluorouracil Activation of p53 Involves an MDM2-Ribosomal Protein Interaction J. Biol. Chem., March 16, 2007; 282(11): 8052 - 8059. [Abstract] [Full Text] [PDF]

				X. Zhao and Y.-T. Yu Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo Nucleic Acids Res., January 28, 2007; 35(2): 550 - 558. [Abstract] [Full Text] [PDF]

				L. Seiple, P. Jaruga, M. Dizdaroglu, and J. T. Stivers Linking uracil base excision repair and 5-fluorouracil toxicity in yeast Nucleic Acids Res., January 10, 2006; 34(1): 140 - 151. [Abstract] [Full Text] [PDF]

				P. Noordhuis, U. Holwerda, C. L. Van der Wilt, C. J. Van Groeningen, K. Smid, S. Meijer, H. M. Pinedo, and G. J. Peters 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers Ann. Onc., July 1, 2004; 15(7): 1025 - 1032. [Abstract] [Full Text] [PDF]

				V. Ramamurthy, S. L. Swann, J. L. Paulson, C. J. Spedaliere, and E. G. Mueller Critical Aspartic Acid Residues in Pseudouridine Synthases J. Biol. Chem., August 6, 1999; 274(32): 22225 - 22230. [Abstract] [Full Text] [PDF]